122 related articles for article (PubMed ID: 9784861)
1. Design, synthesis and biological evaluation of nonpeptide integrin antagonists.
Nicolaou KC; Trujillo JI; Jandeleit B; Chibale K; Rosenfeld M; Diefenbach B; Cheresh DA; Goodman SL
Bioorg Med Chem; 1998 Aug; 6(8):1185-208. PubMed ID: 9784861
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist.
Kumar CC; Malkowski M; Yin Z; Tanghetti E; Yaremko B; Nechuta T; Varner J; Liu M; Smith EM; Neustadt B; Presta M; Armstrong L
Cancer Res; 2001 Mar; 61(5):2232-8. PubMed ID: 11280792
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of angiogenesis in vitro and in vivo: comparison of the relative activities of triflavin, an Arg-Gly-Asp-containing peptide and anti-alpha(v)beta3 integrin monoclonal antibody.
Sheu JR; Yen MH; Kan YC; Hung WC; Chang PT; Luk HN
Biochim Biophys Acta; 1997 Oct; 1336(3):445-54. PubMed ID: 9367172
[TBL] [Abstract][Full Text] [Related]
4. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels.
Brooks PC; Montgomery AM; Rosenfeld M; Reisfeld RA; Hu T; Klier G; Cheresh DA
Cell; 1994 Dec; 79(7):1157-64. PubMed ID: 7528107
[TBL] [Abstract][Full Text] [Related]
5. A novel disintegrin salmosin inhibits tumor angiogenesis.
Kang IC; Lee YD; Kim DS
Cancer Res; 1999 Aug; 59(15):3754-60. PubMed ID: 10446992
[TBL] [Abstract][Full Text] [Related]
6. Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo.
Silletti S; Kessler T; Goldberg J; Boger DL; Cheresh DA
Proc Natl Acad Sci U S A; 2001 Jan; 98(1):119-24. PubMed ID: 11134507
[TBL] [Abstract][Full Text] [Related]
7. Use of the 10-day-old chick embryo model for studying angiogenesis.
Brooks PC; Montgomery AM; Cheresh DA
Methods Mol Biol; 1999; 129():257-69. PubMed ID: 10494570
[No Abstract] [Full Text] [Related]
8. Obtustatin: a potent selective inhibitor of alpha1beta1 integrin in vitro and angiogenesis in vivo.
Marcinkiewicz C; Weinreb PH; Calvete JJ; Kisiel DG; Mousa SA; Tuszynski GP; Lobb RR
Cancer Res; 2003 May; 63(9):2020-3. PubMed ID: 12727812
[TBL] [Abstract][Full Text] [Related]
9. Isoxazolines as potent antagonists of the integrin alpha(v)beta(3).
Pitts WJ; Wityak J; Smallheer JM; Tobin AE; Jetter JW; Buynitsky JS; Harlow PP; Solomon KA; Corjay MH; Mousa SA; Wexler RR; Jadhav PK
J Med Chem; 2000 Jan; 43(1):27-40. PubMed ID: 10633036
[TBL] [Abstract][Full Text] [Related]
10. Thiophene-based vitronectin receptor antagonists.
Bubenik M; Meerovitch K; Bergeron F; Attardo G; Chan L
Bioorg Med Chem Lett; 2003 Feb; 13(3):503-6. PubMed ID: 12565960
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of highly potent and selective hetaryl ureas as integrin alpha(V)beta3-receptor antagonists.
Lange UE; Backfisch G; Delzer J; Geneste H; Graef C; Hornberger W; Kling A; Lauterbach A; Subkowski T; Zechel C
Bioorg Med Chem Lett; 2002 May; 12(10):1379-82. PubMed ID: 11992781
[TBL] [Abstract][Full Text] [Related]
12. A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy.
Carron CP; Meyer DM; Pegg JA; Engleman VW; Nickols MA; Settle SL; Westlin WF; Ruminski PG; Nickols GA
Cancer Res; 1998 May; 58(9):1930-5. PubMed ID: 9581835
[TBL] [Abstract][Full Text] [Related]
13. [Inhibition of angiogenesis properties by SZ-21].
Sheng M; Hu XH; Ruan CG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Feb; 11(1):74-80. PubMed ID: 12667295
[TBL] [Abstract][Full Text] [Related]
14. Rhodostomin, a snake venom disintegrin, inhibits angiogenesis elicited by basic fibroblast growth factor and suppresses tumor growth by a selective alpha(v)beta(3) blockade of endothelial cells.
Yeh CH; Peng HC; Yang RS; Huang TF
Mol Pharmacol; 2001 May; 59(5):1333-42. PubMed ID: 11306719
[TBL] [Abstract][Full Text] [Related]
15. The chick embryo chorioallantoic membrane as a model for in vivo research on angiogenesis.
Ribatti D; Vacca A; Roncali L; Dammacco F
Int J Dev Biol; 1996 Dec; 40(6):1189-97. PubMed ID: 9032025
[TBL] [Abstract][Full Text] [Related]
16. Nonpeptide alpha(v)beta(3) antagonists. 1. Transformation of a potent, integrin-selective alpha(IIb)beta(3) antagonist into a potent alpha(v)beta(3) antagonist.
Duggan ME; Duong LT; Fisher JE; Hamill TG; Hoffman WF; Huff JR; Ihle NC; Leu CT; Nagy RM; Perkins JJ; Rodan SB; Wesolowski G; Whitman DB; Zartman AE; Rodan GA; Hartman GD
J Med Chem; 2000 Oct; 43(20):3736-45. PubMed ID: 11020288
[TBL] [Abstract][Full Text] [Related]
17. alpha(v)beta(3) Antagonists based on a central thiophene scaffold.
Peyman A; Scheunemann K; Will DW; Knolle J; Wehner V; Breipohl G; Stilz HU; Carniato D; Ruxer J; Gourvest J; Auberval M; Doucet B; Baron R; Gaillard M; Gadek TR; Bodary S
Bioorg Med Chem Lett; 2001 Aug; 11(15):2011-5. PubMed ID: 11454469
[TBL] [Abstract][Full Text] [Related]
18. Potent inhibition of angiogenesis by wortmannin, a fungal metabolite.
Oikawa T; Shimamura M
Eur J Pharmacol; 1996 Dec; 318(1):93-6. PubMed ID: 9007518
[TBL] [Abstract][Full Text] [Related]
19. Chorioallantoic membrane capillary bed: a useful target for studying angiogenesis and anti-angiogenesis in vivo.
Ribatti D; Nico B; Vacca A; Roncali L; Burri PH; Djonov V
Anat Rec; 2001 Dec; 264(4):317-24. PubMed ID: 11745087
[TBL] [Abstract][Full Text] [Related]
20. New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: the gelatin sponge/chorioallantoic membrane assay.
Ribatti D; Gualandris A; Bastaki M; Vacca A; Iurlaro M; Roncali L; Presta M
J Vasc Res; 1997; 34(6):455-63. PubMed ID: 9425998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
